Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections

Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor si...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Thorac Cancer
Päätekijät: Lu, Minya, Zhang, Li, Li, Yue, Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Si, Xiaoyan, Xu, Yingchun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons Australia, Ltd 2020
Aiheet:
Clinical Guideline
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049502/
https://ncbi.nlm.nih.gov/pubmed/31970940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13313
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia